130 related articles for article (PubMed ID: 29807678)
61. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
[TBL] [Abstract][Full Text] [Related]
63. Noninferiority of
Dai D; Rollo FD; Bryant J; Kim EE
Contrast Media Mol Imaging; 2018; 2018():8969714. PubMed ID: 29736155
[No Abstract] [Full Text] [Related]
64. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
65. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
67. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
[TBL] [Abstract][Full Text] [Related]
68. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
69. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
Seol HY; Kim YS; Kim SJ
Oncology; 2021; 99(2):96-104. PubMed ID: 32980838
[TBL] [Abstract][Full Text] [Related]
70. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
[TBL] [Abstract][Full Text] [Related]
71. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer.
van Loon J; van Baardwijk A; Boersma L; Ollers M; Lambin P; De Ruysscher D
Cancer Treat Rev; 2011 Aug; 37(5):331-43. PubMed ID: 21320756
[TBL] [Abstract][Full Text] [Related]
72. Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer.
Salminen E; Mac Manus M
Ann Med; 2001 Sep; 33(6):404-9. PubMed ID: 11585101
[TBL] [Abstract][Full Text] [Related]
73. Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer.
Mac Manus MP
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):510-20. PubMed ID: 20927018
[TBL] [Abstract][Full Text] [Related]
74. PET and PET-CT of lung cancer.
Steinert HC
Methods Mol Biol; 2011; 727():33-51. PubMed ID: 21331927
[TBL] [Abstract][Full Text] [Related]
75. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
76. [Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
Bury T; Corhay JL; Paulus P; Weber T; D'Harcour JB; Limet R; Rigo P; Radermecker MF
Rev Mal Respir; 1996 Jul; 13(3):281-6. PubMed ID: 8765921
[TBL] [Abstract][Full Text] [Related]
77. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
[TBL] [Abstract][Full Text] [Related]
78. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
79. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
80. Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.
Ko KH; Hsu HH; Huang TW; Gao HW; Cheng CY; Hsu YC; Chang WC; Chu CM; Chen JH; Lee SC
Medicine (Baltimore); 2015 Jan; 94(3):e434. PubMed ID: 25621697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
